Clinical trials: SARS-CoV-2 Virus Infection
COVID-19
Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines
A phase 1/2, open-label clinical trial in individuals, 18 years of age and older, who are in good health, have no known history of Coronavirus Disease 2019 (COVID-19) or Severe Acute Respiratory Syndrome Coronavirus 2…
- Trial name
- NCT04889209
- Testing
- Ad26.COV2.S, BNT162b2, mRNA-1273
- Where
- 10 sites in United States
- Volunteers
- 867 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
Evaluation of Vitamin A and E Deficiency With Severity of SARS-COV-2 Disease: A Case-Control Study
Coronavirus disease 2019 (COVID-19) is a novel infectious disease that has been spreading worldwide Coronaviridae study group of the International Committee on taxonomy of viruses (2020).
- Trial name
- NCT05946499
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Cairo University
Sars-CoV2, Cancer
Prospective Analysis of Morbi-mortality of Patients With Cancers in Active Phase of Treatment Suspected or Diagnosed of a SARS-CoV-2 Infection
National multicentre epidemiological study to describe retrospectively and prospectively the clinical outcomes of patients with a suspected coronavirus infection (either confirmed or not) while receiving a medical treatment for…
- Trial name
- ONCOVID-19 (NCT04363632)
- Where
- 18 sites in France
- Volunteers
- 1,231 people
- Sponsor
- Centre Leon Berard
Covid19
Singapore COVID-19 Chemosensory Tracking (SCCT) Study
The study aims to longitudinally track the onset, severity and recovery of changes in chemosensory acuity (smell and/or taste loss) among those suspected of COVID-19 infection.
- Trial name
- NCT04492904
- Testing
- Home-use Test and Follow-up Questionnaire
- Where
- Singapore
- Volunteers
- 102 people
- Sponsor
- Singapore Institute of Food and Biotechnology Innovation
Coronavirus Infection, COVID
Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS)
Specific Aims: 1. The investigators will prospectively evaluate and analyze changes in the appearance of the lungs and heart through serial acquisition of focused point-of-care ultrasound images in a cohort of patients with or…
- Conditions
- Coronavirus Infection, COVID, Covid-19, SARS-CoV-2
- Trial name
- NCT04339998
- Testing
- Point-of-Care Ultrasonography (POCUS)
- Where
- 2 sites in United States
- Volunteers
- 129 people
- Sponsor
- University of Minnesota
COVID-19
Investigation of Subsequent and Co-infections Associated With SARS-CoV-2 (COVID-19)
Multicenter retrospective chart review of patients admitted to any of the four Methodist Health System hospitals
- Trial name
- NCT04561193
- Testing
- Observational
- Where
- United States
- Volunteers
- 417 people
- Sponsor
- Methodist Health System
Coronavirus Infection, Severe Acute Respiratory Syndrome
COVID-19 Seroprevalence Study in French Guiana
Serological surveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies in the population to assess the extent of the infection and the COVID-19 immunity of the population in French Guiana.
- Conditions
- Coronavirus Infection, Severe Acute Respiratory Syndrome, SARS-CoV Infection, Covid19
- Trial name
- EPI-COVID-POP (NCT04490850)
- Testing
- Blood sample
- Where
- 5 sites in French Guiana
- Volunteers
- 3,541 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
COVID-19
Brequinar Combined With Dipyridamole in Patients With Mild to Moderate COVID-19
A Phase 2 multi-center, assessor-blind, randomized study to assess the safety, tolerability, and antiviral activity of brequinar in combination with dipyridamole.
- Trial name
- CCBCRISIS04 (NCT05166876)
- Testing
- Brequinar Sodium, Dipyridamole 75 MG
- Where
- 7 sites in India
- Volunteers
- 26 people
- Sponsor
- Clear Creek Bio, Inc.
COVID-19
Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults
This is a multicenter, US-only, phase 1, open-label, dose escalation, non-randomized study of the safety, tolerability, and immunogenicity of investigational ChAd and SAM SARS-CoV-2 vaccines in healthy adult subjects.
- Trial name
- NCT04776317
- Testing
- ChAdV68-S, ChAdV68-S-TCE, SAM-LNP-S
- Where
- 4 sites in United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Long COVID, Post COVID-19 Condition
Investigating the Effectiveness of Vimida
This randomized controlled trial (RCT) with 160 patients suffering from fatigue after COVID-19 infection aims to investigate the effectiveness of the unguided digital therapeutic vimida for reducing post-COVID-19 fatigue.
- Trial name
- InvidiCO (NCT06251518)
- Testing
- vimida
- Where
- Germany
- Volunteers
- 160 people
- Sponsor
- Gaia AG
Coronavirus Infections
COVID-19 Patients Characterization, Biobank, Treatment Response and Outcome Predictor
Collection and analysis of demographic, clinical, radiographic and laboratory characteristics of CoViD-19 patients to identify predictors of disease severity, mortality and treatment response, and to identify subgroup of patients…
- Trial name
- COVID-BioB (NCT04318366)
- Testing
- Observational Study
- Where
- 13 sites in Italy
- Volunteers
- 6,000 people
- Sponsor
- Università Vita-Salute San Raffaele
Coronavirus Infection
Prevalence and Incidence of COVID-19 Infection in Patients With Chronic Plaque Psoriasis on Immunosuppressant Therapy
This study will assess the prevalence and incidence of COVID-19 infection in patients with chronic plaque psoriasis on immunosuppressant therapy.
- Trial name
- NCT04324866
- Testing
- Nasopharyngeal swab
- Volunteers
- 300 people
- Sponsor
- Universita di Verona
COVID-19, Encephalopathy
Acute Encephalopathy in Critically Ill Patients With COVID-19
Infection with SARS-CoV-2 or severe acute respiratory syndrome coronarvirus type 2 was highlighted in December 2019 in the city of Wuhan in China, responsible for an pandemic evolution since March 11, 2020.
- Conditions
- COVID-19, Encephalopathy, Critically Ill
- Trial name
- NeuroCOVID19 (NCT04320472)
- Testing
- Follow up
- Where
- 39 sites in United States, Brazil and 5 more
- Volunteers
- 250 people
- Sponsor
- Ictal Group
COVID-19
Evaluation of Ganovo （Danoprevir ） Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection
Evaluation of the efficacy and safety of Ganovo combined with ritonavir for patients infected with SARS-CoV-2.
- Trial name
- NCT04291729
- Testing
- Ganovo+ritonavir+/-Interferon nebulization
- Where
- China
- Volunteers
- 11 people
- Sponsor
- The Ninth Hospital of Nanchang
COVID, Corona Virus Infection
Intensive Care Associated Complications and Outcome of Acute Respiratory Distress Syndrome Due to COVID-19
COVID-19 patients with a severely symptomatic progression with development of an Acute respiratory distress syndrome (ARDS) due to SARS-CoV-2 need prolonged intensive care treatment involving pharmacological immobilization…
- Conditions
- COVID, Corona Virus Infection, Sars-CoV2
- Trial name
- NCT04397172
- Testing
- Study Arm
- Where
- Switzerland
- Volunteers
- 48 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
SARS-CoV 2, COVID
Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19
Brief Summary: SARS-CoV-2 virus infection is known to cause Lung Injury that begins as dyspnea and exercise intolerance, but may rapidly progress to Critical COVID-19 with Respiratory Failure and the need for noninvasive or…
- Conditions
- SARS-CoV 2, COVID, ARDS, ALI
- Trial name
- AVICOVID-3 (NCT05137795)
- Testing
- ZYESAMI™ (aviptadil acetate)
- Sponsor
- APR Applied Pharma Research s.a.
Cytokine Storm (Covid-19)
Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm
This was a randomized, double-blind, placebo-controlled, 29-day, multicenter study to assess the efficacy and safety of ruxolitinib + standard-of-care (SoC) therapy, compared with placebo + SoC therapy, in patients aged ≥12 years…
- Trial name
- RUXCOVID (NCT04362137)
- Testing
- Ruxolitinib
- Where
- 61 sites in United States, Argentina and 10 more
- Volunteers
- 432 people
- Sponsor
- Novartis Pharmaceuticals
COVID-19 Prevention
Safety, Tolerability, and Pharmacokinetics of Q-Griffithsin Intranasal Spray
The purpose of this study is to test the safety of multiple doses of a Q-GRFT nasal spray in healthy volunteers. This Q-GRFT nasal spray is "investigational and not approved by the FDA for general use" and is being developed to…
- Trial name
- NCT05437029
- Testing
- Q-Griffithsin 3.0, Q-Griffithsin 6.0
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Kenneth Palmer
COVID-19
Efficacy and Safety of Hydroxychloroquine and Azithromycin for Patients With Moderate to Severe COVID-19
This is an exploratory study to evaluate the efficacy of hydroxychloroquine (400 mg BID on D1 and 400 mg/day on D2 to D5) and azithromycin (500 mg/ 5 days) to treat moderate to severe COVID-19 pneumonia.
- Trial name
- NCT04329572
- Testing
- Hydroxychloroquine Sulfate, Azithromycin Tablets
- Where
- Brazil
- Volunteers
- 400 people
- Sponsor
- Azidus Brasil
Covid-19, Critical Illness
MIcrovascular Dysfunction in CRitically Ill cOVID-19 Patients
Microcirculatory dysfunction appears to play a key role in the development of organ failure leading to the death of patients with coronavirus disease 2019 (Covid-19).
- Conditions
- Covid-19, Critical Illness, Hemodynamics, SARS-CoV Infection
- Trial name
- MICROVID (NCT04819802)
- Testing
- Measurement of sublingual microcirculation, Plasma sampling
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris